Stockwinners Market Radar for March 16, 2025 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:57 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1) Goldman Sachs (GS) cut its oil price forecasts as tariffs reduce the outlook for U.S. growth, Yongchang Chin of Bloomberg reports. "The medium-term risks to our forecast remain to the downside given potential further tariff escalation and potentially longer OPEC+ production increases," they said. 2) Virgin Atlantic Airways is grouping with Joby Aviation (JOBY) to offer passengers in the U.K. seamless booking and quicker travel to and from airports once air taxi service in approved in the country, Chester Dawson of Bloomberg reports. 3) Porsche (POAHY), the majority shareholder of Volkswagen (VWAGY), is not planning to sell Volkswagen shares, Reuters reports. The news comes after a newspaper report stating it was weighing such a move. 4) Baidu (BIDU) launched its latest foundation models, including native multimodal foundation model ERNIE 4.5 and deep-thinking reasoning model ERNIE X1. Both models are now freely accessible to individual users through ERNIE Bot's official website. 5) Seaport Research upgraded Liberty Formula (FWONK) One to Buy from Neutral with a $96 price target. The stock has become oversold on tariff and geopolitical-related consumer spending fears and on a near-term media rights renewal possibly losing one of its bidders, but most of the company's revenue streams are contracted and therefore should operationally be insulated from recessionary effects, the analyst tells investors in a research note.

19:53 EDT Dyne announces new long-term data from Phase 1/2 DELIVER trial of DYNE-251 - Dyne Therapeutics announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented and sustained functional improvement at the selected registrational dose of 20 mg/kg Q4W. The DELIVER trial is evaluating DYNE-251 in individuals with Duchenne muscular dystrophy who are amenable to exon 51 skipping, and updated results from the trial are being presented this week at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference. Key findings from the DELIVER Phase 1/2 trial presentation include: Function: Meaningful and sustained improvements from baseline in multiple functional endpoints were observed in both the 20 mg/kg and 10 mg/kg1 DYNE-251 Q4W cohorts, through 12 and 18 months, respectively. Functional assessments included Stride Velocity 95th Centile, North Star Ambulatory Assessment, 10-Meter Walk/Run Time, and Time to Rise from Floor.

18:47 EDT Rocket Lab successfully launches 61st electron mission - Rocket Lab USA successfully launched its second mission for Japanese customer, the Institute for Q-shu Pioneers of Space, iQPS. 'The Lightning God Reigns' mission lifted-off from Rocket Lab Launch Complex 1 in Mahia, New Zealand at 1:00 p.m. NZDT on March 15, 2025 to successfully deploy iQPS' QPS-SAR-9 spacecraft to a 575km circular Earth orbit. The mission follows Rocket Lab's first launch for the company in December 2023, when Electron deployed another QPS-SAR satellite as part of iQPS' newly established radar imaging constellation.

18:43 EDT AbbVie announces final analysis of Phase 3 MIRASOL trial - AbbVie announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE in women with folate receptor alpha-positive platinum-resistant ovarian cancer compared to chemotherapy. At 30.5 months median follow-up, treatment with ELAHERE continued to show significant improvements in progression-free survival and overall survival compared to investigator's choice chemotherapy. Key findings from the 30.5-month median follow-up include: ELAHERE treatment achieved superior efficacy versus IC chemotherapy, with a median PFS of 5.59 months versus 3.98 months, representing a 37% reduction in the risk of tumor progression or death and a higher objective response rate of 41.9% versus 15.9%. Superior and clinically meaningful overall survival for patients receiving ELAHERE (median 16.85 months) compared to IC chemotherapy, representing a 32% reduction in the risk of death. Other endpoints included safety and duration of response (DOR), which were consistent with the primary data analysis at 13.1-months median follow-up.

18:37 EDT Sutro Biopharma presents expanded data from REFRalphaME-01 trial - Sutro Biopharma announced expanded data in a late-breaking oral presentation from the dose-optimization portion of the REFRalphaME-O1 trial with luveltamab tazevibulin in patients with platinum resistant ovarian cancer at the Society of Gynecologic Oncology, SGO, Annual Meeting on Women's Cancer. The SGO Annual Meeting will take place from March 14-17, 2025 in Seattle, Washington. In this study, luvelta demonstrated encouraging antitumor activity in patients with late-stage ovarian cancer across all levels of Folate Receptor-alpha expression of 25% or greater, including an improved overall response rate, ORR, a low discontinuation rate, and a consistent safety profile across dose levels. Based on these findings, Sutro selected the optimized dose of luvelta: 5.2 mg/kg + G-CSF for two cycles then continued on 4.3 mg/kg.